Backup origins: their role in replication fork recovery and tumor suppression
Backup origins: their role in replication fork recovery and tumor suppression
批准号:
8036109
负责人:
Naoko Shima
金额:
$29.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2014-12-31
关键词:
Automobile DrivingBindingCancer EtiologyCell CycleCellsChromatinChromosome Fragile SitesChromosomesComplexCopy Number PolymorphismCytogenetic AnalysisDNADNA Sequence RearrangementDNA biosynthesisDevelopmentDiagnostic Neoplasm StagingEnsureEventFiberFire - disastersG1 PhaseGenesGenetic Crossing OverGenetic RecombinationGenomeGenomic InstabilityGoalsImpairmentKnowledgeLicensingLoss of HeterozygosityMCM2 geneMalignant NeoplasmsMediatingMusMutant Strains MiceOutcomePathway interactionsPenetrancePlayProcessRecoveryReplication OriginRiskRoleS PhaseTestingTransgenic OrganismsTravelTumor Suppressionabstractingcancer preventioncancer therapychromatin immunoprecipitationhelicasehomologous recombinationhuman diseaseinnovationmammalian genomepreventpublic health relevancesingle moleculetumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Abstract: Origin licensing ensures that the eukaryotic genome is replicated precisely once per cell cycle. During the G1 phase, replication origins are licensed by the binding of MCM2-7 complexes, the replicative helicases, and are regulated to fire only once during S phase. It is believed that MCM2-7 complexes exist on chromatin in a >10-fold excess over active replication origins, and that unused MCM2-7 complexes are most likely displaced from the chromatin by ongoing replication forks during S phase. The reason for this overabundance of the MCM2-7 complexes on chromatin has remained largely unknown. However, a current hypothesis proposes that these excess MCM2-7 complexes are dispensable in normal S phase but are required to survive perturbed S phase as they provide backup origins. Here, we propose that these backup origins exist abundantly because their use allows for the rescue of stalled forks in a recombination-free manner. Moreover, this anti-recombinogenic role of backup origins is required for tumor suppression, because a ~50% loss of backup origins leads to spontaneous tumorigenesis in Mcm4Chaos3/Chaos3 mice with complete penetrance. The goal of this proposal is to unravel the role of backup origins in tumor suppression using Mcm4Chaos3 mice. The following are our specific aims. 1) Demonstrate that backup origin rescue is reduced in Mcm4Chaos3/Chaos3 cells. The use of backup origins and their role in fork recovery will be tested using a single molecule analysis called DNA fiber. 2) Demonstrate that chromosome regions with few backup origins are fragile. By combining chromatin immunoprecipitation (ChIP) on chip and cytogenetic analyses, we will test backup origin levels as one of the determining factors for common fragile sites, specific loci particularly susceptible to fork stalling. 3) Prove that backup origins suppress homologous recombination and tumorigenesis. We will determine the role of backup origins in suppressing illegitimate recombination using a transgenic locus called FYDR. The contribution of excessive homologous recombination to Mcm4Chaos3 tumorigenesis will be tested in a BLM- deficient background to resolve recombination intermediates via crossing-over. 4) Test if the loss of backup origins and homologous recombination is synthetic lethal. To test the critical contribution of backup origins to fork recovery, we will determine if concomitant impairment of backup origin rescue and homologous recombination results in synthetic lethality and tumor suppression. The expected outcomes would have a significant impact on our understanding of pathway choice for fork recovery and developing new cancer therapies, as the role of backup origins has been largely ignored. Furthermore, the expected results will demonstrate that under-licensing of replication origins alone causes cancer, strengthening the current view that deregulated origin licensing has a causative role for the genome instability observed in cancer.
PUBLIC HEALTH RELEVANCE: Project Narrative: This application focuses on the events that may happen in very early stages of cancer development. The goal of this proposal is to provide information for the development of new cancer therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic mechanisms of Mitotic DNA synthesis in mammalian cells
-
批准号:10033544
-
项目类别:
-
资助金额:$30.28万
-
财政年份:2020
-
负责人:Naoko Shima
-
依托单位:
Genetic mechanisms of Mitotic DNA synthesis in mammalian cells
-
批准号:10652323
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2020
-
负责人:Naoko Shima
-
依托单位:
Genetic mechanisms of Mitotic DNA synthesis in mammalian cells
-
批准号:10248470
-
项目类别:
-
资助金额:$30.69万
-
财政年份:2020
-
负责人:Naoko Shima
-
依托单位:
Genetic mechanisms of Mitotic DNA synthesis in mammalian cells
-
批准号:10441544
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2020
-
负责人:Naoko Shima
-
依托单位:
Exploiting replication stress for the selective killing of FGFR-dependent cancers
-
批准号:8878498
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2015
-
负责人:Naoko Shima
-
依托单位:
Backup origins: their role in replication fork recovery and tumor suppression
-
批准号:8403816
-
项目类别:
-
资助金额:$27.96万
-
财政年份:2010
-
负责人:Naoko Shima
-
依托单位:
Backup origins: their role in replication fork recovery and tumor suppression
-
批准号:8600655
-
项目类别:
-
资助金额:$28.83万
-
财政年份:2010
-
负责人:Naoko Shima
-
依托单位:
Backup origins: their role in replication fork recovery and tumor suppression
-
批准号:8206458
-
项目类别:
-
资助金额:$29.76万
-
财政年份:2010
-
负责人:Naoko Shima
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: